https://www.pharmaradar360.com/article/immunoglobulin-when-to-use-2bc3407cfc7e587bPharma Surgeen2026-07-31T14:47:36.000ZImmunoglobulin: when to usehttps://www.pharmaradar360.com/article/silicon-valley-looks-to-a-new-biotech-frontier-montana-e61575a238363bddPharma Surgeen2026-07-31T14:36:00.000ZSilicon Valley Looks to a New Biotech Frontier: Montanahttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-august-2026-1b10eeb5524e0803Pharma Surgeen2026-07-31T14:32:17.000ZUK Clinical Research Delivery key performance indicators: data to August 2026https://www.pharmaradar360.com/article/acute-kidney-injury-causes-diagnosis-and-management-fa7cafeb9e7d0398Pharma Surgeen2026-07-31T14:28:32.000ZAcute kidney injury: causes, diagnosis and managementhttps://www.pharmaradar360.com/article/moleculin-biotech-prices-9-3-million-public-offering-9dc6327d4e2e421fPharma Surgeen2026-07-31T14:19:46.000ZMoleculin Biotech prices $9.3 million public offeringhttps://www.pharmaradar360.com/article/malaria-prevention-guidelines-for-travellers-from-the-uk-2026-bfdb8582fd85690ePharma Surgeen2026-07-31T14:00:56.000ZMalaria prevention guidelines for travellers from the UK 2026https://www.pharmaradar360.com/article/krystal-biotech-earnings-in-focus-as-vyjuvek-expansion-accelerates-bd43ca270a6d2d15Pharma Surgeen2026-07-31T13:58:00.000ZKrystal Biotech earnings in focus as Vyjuvek expansion accelerateshttps://www.pharmaradar360.com/article/vanguard-capital-management-coll-discloses-5-01-passive-stake-in-collegium-15f64aa947d7d558Pharma Surgeen2026-07-31T13:55:21.000ZVanguard Capital Management (COLL) discloses 5.01% passive stake in Collegiumhttps://www.pharmaradar360.com/article/c16-biosciences-builds-palm-free-beauty-toolkit-with-biotech-ingredient-trio-1b508dcc07634583Pharma Surgeen2026-07-31T13:44:51.000ZC16 Biosciences builds palm-free beauty toolkit with biotech ingredient triohttps://www.pharmaradar360.com/article/government-takes-action-to-crack-down-on-rogue-funeral-operators-d91be37e803eb3b6Pharma Surgeen2026-07-31T13:39:25.000ZGovernment takes action to crack down on rogue funeral operatorshttps://www.pharmaradar360.com/article/fda-panel-backs-unapproved-peptides-despite-safety-concerns-22833d81f60e2149Pharma Surgeen2026-07-31T13:14:56.000ZFDA panel backs unapproved peptides despite safety concernshttps://www.pharmaradar360.com/article/biotech-stocks-facing-fda-decision-in-august-2026-713c235e44d8ba49Pharma Surgeen2026-07-31T13:13:00.000ZBiotech Stocks Facing FDA Decision In August 2026https://www.pharmaradar360.com/article/renaissance-wages-war-on-wireworms-in-new-challenge-for-targeted-biotech-c484c1b25b56c844Pharma Surgeen2026-07-31T13:11:37.000ZRenaissance Wages War on Wireworms in New Challenge for Targeted Biotechhttps://www.pharmaradar360.com/article/moleculin-biotech-mbrx-reports-preliminary-phase-2-3-trial-dat-ea8709bc2a49a7fbPharma Surgeen2026-07-31T13:09:20.000ZMoleculin Biotech (MBRX) Reports Preliminary Phase 2/3 Trial Dathttps://www.pharmaradar360.com/article/fierce-pharma-asia-legend-ceo-exits-merck-s-hush-hush-pd-1xvegf-plan-otsuka-s-no-94b8841a996fb9bePharma Surgeen2026-07-31T13:00:00.000ZFierce Pharma Asia—Legend CEO exits; Merck’s hush-hush PD-1xVEGF plan; Otsuka’s novel ADHD nodhttps://www.pharmaradar360.com/article/this-biotech-stock-is-soaring-132-after-key-fda-panel-vote-on-skin-cancer-treatm-387d85c0a75182dcPharma Surgeen2026-07-31T12:52:00.000ZThis Biotech Stock Is Soaring 132% After Key FDA Panel Vote on Skin Cancer Treatmenthttps://www.pharmaradar360.com/article/novo-nordisk-ziltivekimab-heart-drug-fails-phase-3-trial-650564f8d6a4717fPharma Surgeen2026-07-31T12:46:15.000ZNovo Nordisk ziltivekimab heart drug fails phase 3 trialhttps://www.pharmaradar360.com/article/legend-ceo-departs-without-successor-in-place-chutes-ladders-f0a93415ee4b72b5Pharma Surgeen2026-07-31T12:29:45.000ZLegend CEO departs without successor in place—Chutes & Laddershttps://www.pharmaradar360.com/article/childhood-vaccination-coverage-provisional-monthly-data-for-england-096cd364d32970b8Pharma Surgeen2026-07-31T12:00:05.000ZChildhood vaccination coverage: provisional monthly data for Englandhttps://www.pharmaradar360.com/article/from-abu-dhabi-to-brazil-every-region-is-vying-for-the-new-emerging-economy-of-b-6f2a1e7ee617add0Pharma Surgeen2026-07-31T12:00:00.000ZFrom Abu Dhabi to Brazil, every region is vying for the ‘new emerging economy’ of biotechhttps://www.pharmaradar360.com/article/spartanburg-pharmaceutical-facility-to-close-layoff-nearly-200-employees-2af42e2daa892d08Pharma Surgeen2026-07-31T11:59:00.000ZSpartanburg pharmaceutical facility to close, layoff nearly 200 employeeshttps://www.pharmaradar360.com/article/abbvie-reports-second-quarter-2026-financial-results-d9247dc287bfbdcfPharma Surgeen2026-07-31T11:47:00.000ZAbbVie Reports Second-Quarter 2026 Financial Resultshttps://www.pharmaradar360.com/article/abbvie-reports-second-quarter-2026-financial-results-94cce4f303cb088aPharma Surgeen2026-07-31T11:47:00.000ZAbbVie Reports Second-Quarter 2026 Financial Resultshttps://www.pharmaradar360.com/article/fda-says-mantralaya-canteen-98-clean-bombay-high-court-orders-lawyers-inspection-144fb601297e148fPharma Surgeen2026-07-31T11:39:35.000ZFDA says Mantralaya canteen 98% clean, Bombay High Court orders lawyers' inspectionhttps://www.pharmaradar360.com/article/biogen-is-scaling-back-acquisitions-and-will-focus-on-its-existing-pipeline-26eda5ded5bafdadPharma Surgeen2026-07-31T11:33:38.000ZBiogen is scaling back acquisitions and will focus on its existing pipelinehttps://www.pharmaradar360.com/article/tenax-therapeutics-reports-q2-net-loss-17-8m-cash-118-0m-level-phase-3-topline-d-a601578f6359503aPharma Surgeen2026-07-31T11:33:00.000ZTenax Therapeutics reports Q2 net loss $17.8M, cash $118.0M; LEVEL Phase 3 topline due Aug 2026https://www.pharmaradar360.com/article/2026-99c693c59e5ca28aPharma Surgeen2026-07-31T11:30:00.000Z日本新薬レポート2026 発刊のお知らせhttps://www.pharmaradar360.com/article/2024-vpag-operational-review-minutes-e2c17cfb6d1983fcPharma Surgeen2026-07-31T11:27:45.000Z2024 VPAG operational review minuteshttps://www.pharmaradar360.com/article/2024-vpag-operational-review-12-august-2025-b4785a30a0d04a7cPharma Surgeen2026-07-31T11:27:36.000Z2024 VPAG operational review: 12 August 2025https://www.pharmaradar360.com/article/warsaw-s-world-first-liver-transplant-puts-eu-biotech-rules-in-the-spotlight-349c167b3d37d4c1Pharma Surgeen2026-07-31T11:23:16.000ZWarsaw’s world-first liver transplant puts EU biotech rules in the spotlighthttps://www.pharmaradar360.com/article/tenax-therapeutics-reports-second-quarter-2026-financial-results-and-provides-co-f3e66e55627d0589Pharma Surgeen2026-07-31T11:20:57.000ZTenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updatehttps://www.pharmaradar360.com/article/ziltivekimab-lowered-inflammation-markers-not-major-heart-events-b1f57f54308644f4Pharma Surgeen2026-07-31T11:20:00.000ZZiltivekimab lowered inflammation markers, not major heart eventshttps://www.pharmaradar360.com/article/vogenx-targets-modest-nasdaq-ipo-to-back-metabolic-drug-fb4f0be0bad0ce73Pharma Surgeen2026-07-31T11:14:44.000ZVogenx targets modest Nasdaq IPO to back metabolic drughttps://www.pharmaradar360.com/article/pharmaceutical-advertising-laws-and-regulations-2026-e066331b823b28e1Pharma Surgeen2026-07-31T11:12:38.000ZPharmaceutical Advertising Laws and Regulations 2026https://www.pharmaradar360.com/article/ono-pharmaceutical-co-ophlf-q1-earnings-and-revenues-top-estimates-c0ce16c42c75c2b1Pharma Surgeen2026-07-31T11:10:02.000ZOno Pharmaceutical Co. (OPHLF) Q1 Earnings and Revenues Top Estimateshttps://www.pharmaradar360.com/article/sun-pharmaceutical-s-consolidated-net-profit-grows-in-fiscal-q1-d5ce9bb255538ce6Pharma Surgeen2026-07-31T11:09:52.000ZSun Pharmaceutical's Consolidated Net Profit Grows in Fiscal Q1https://www.pharmaradar360.com/article/who-proposes-regulatory-recommendations-to-support-pharmaceutical-decarbonisatio-5ad4c0fee9eaa1b7Pharma Surgeen2026-07-31T11:09:42.000ZWHO proposes regulatory recommendations to support pharmaceutical decarbonisationhttps://www.pharmaradar360.com/article/ai-cognitive-health-startup-mantis-biotech-rethinks-how-women-are-diagnosed-f76c27fb21c72b0cPharma Surgeen2026-07-31T11:00:21.000ZAI Cognitive Health Startup Mantis Biotech Rethinks How Women Are Diagnosedhttps://www.pharmaradar360.com/article/tiziana-reports-reduction-in-brain-inflammation-in-third-multiple-system-atrophy-3334e696b004f349Pharma Surgeen2026-07-31T11:00:00.000ZTiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumabhttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-55ceb61127210686Pharma Surgeen2026-07-31T10:58:07.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-cort-30-neog-22-bax-7-with-quarterly-results-tra-f6b2f9374c8d5078Pharma Surgeen2026-07-31T10:57:00.000ZBiotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCRhttps://www.pharmaradar360.com/article/tempufen-antalia-pharma-603c48a9f89affafPharma Surgeen2026-07-31T10:53:30.000ZΑπαγόρευση κυκλοφορίας του προϊόντος TEMPUFEN της εταιρείας ANTALIA PHARMA ΜΟΝΟΠΡΟΣΩΠΗ Ι.Κ.Ε.https://www.pharmaradar360.com/article/sun-pharmaceutical-industries-limited-reports-earnings-results-for-the-first-qua-475cdc219e0f989aPharma Surgeen2026-07-31T10:35:43.000ZSun Pharmaceutical Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2026https://www.pharmaradar360.com/article/china-leapfrogs-into-global-biotech-9553b32aef69edf5Pharma Surgeen2026-07-31T10:29:42.000ZChina Leapfrogs into Global Biotechhttps://www.pharmaradar360.com/article/proposed-coins-act-seeks-to-restrict-u-s-capital-investment-in-chinese-biotech-s-33e968278fcc1c36Pharma Surgeen2026-07-31T10:20:15.000ZProposed COINS Act Seeks to Restrict U.S. Capital Investment in Chinese Biotech Sectorhttps://www.pharmaradar360.com/article/boosting-cgt-access-a-global-consideration-with-wide-spanning-benefits-344e64e1b8ac9618Pharma Surgeen2026-07-31T10:16:09.000ZBoosting CGT access: a global consideration with wide-spanning benefitshttps://www.pharmaradar360.com/article/how-pharmacists-are-storing-medicines-in-soaring-temperatures-c698fbec0d94f95fPharma Surgeen2026-07-31T10:09:02.000ZHow pharmacists are storing medicines in soaring temperatureshttps://www.pharmaradar360.com/article/rbf-capital-llc-sells-30-000-shares-of-teva-pharmaceutical-industries-ltd-teva-d1b7f1b4fa010142Pharma Surgeen2026-07-31T10:06:52.000ZRBF Capital LLC Sells 30,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/a-new-kind-of-hiv-pill-just-passed-its-first-test-in-humans-09e2921a97f76f27Pharma Surgeen2026-07-31T10:03:40.000ZA New Kind of HIV Pill Just Passed Its First Test in Humanshttps://www.pharmaradar360.com/article/sun-pharma-s-quarterly-profit-jumps-on-strength-in-specialty-medicines-a6c59eda54ada6a6Pharma Surgeen2026-07-31T10:03:17.000ZSun Pharma's quarterly profit jumps on strength in specialty medicineshttps://www.pharmaradar360.com/article/pune-food-safety-crackdown-fda-suspends-21-establishments-seizes-50-65-lakh-wort-49b2eafbf6b6b526Pharma Surgeen2026-07-31T09:49:18.000ZPune Food Safety Crackdown: FDA Suspends 21 Establishments, Seizes ₹50.65 Lakh Worth of Goodshttps://www.pharmaradar360.com/article/the-national-gonorrhoea-vaccination-programme-using-4cmenb-vaccine-frequently-as-479b1a7456a61302Pharma Surgeen2026-07-31T09:44:52.000ZThe national gonorrhoea vaccination programme using 4CMenB vaccine: frequently asked questionshttps://www.pharmaradar360.com/article/cordis-project-livemap-live-cell-mapping-of-drug-protein-interactions-across-the-c69f77badafedf2aPharma Surgeen2026-07-31T09:42:43.000ZCORDIS project: LIVEMAP: Live-cell mapping of drug–protein interactions across the human proteomehttps://www.pharmaradar360.com/article/cordis-project-short-tandem-repeat-instability-quantifier-for-next-generation-se-e8e1babd8e9b60d4Pharma Surgeen2026-07-31T09:42:38.000ZCORDIS project: Short Tandem Repeat Instability QuantIfier for Next-Generation sequencinghttps://www.pharmaradar360.com/article/cordis-project-harnessing-biobanking-organ-models-and-patient-empowerment-for-a-b5f2b1795336368aPharma Surgeen2026-07-31T09:40:23.000ZCORDIS project: Harnessing biobanking, Organ models, and Patient Empowerment for a better quality of life for women living within Polyendocrine Metabolic Ovary Syndromehttps://www.pharmaradar360.com/article/cordis-project-targeting-tumour-cell-plasticity-in-colorectal-cancer-78e51cb07241d842Pharma Surgeen2026-07-31T09:40:18.000ZCORDIS project: Targeting Tumour Cell Plasticity in Colorectal Cancerhttps://www.pharmaradar360.com/article/european-drug-manufacturers-under-threat-from-proposed-us-supply-chain-bill-83c2d26863857af7Pharma Surgeen2026-07-31T09:36:09.000ZEuropean drug manufacturers under threat from proposed US supply chain billhttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-mhra-phase-i-accreditation-scheme-0a6f6f31a937b2b5Pharma Surgeen2026-07-31T09:31:24.000ZClinical trials for medicines: MHRA phase I accreditation schemehttps://www.pharmaradar360.com/article/cell-and-gene-therapy-manufacturers-turn-to-specialist-automation-partners-19344ef2e745035aPharma Surgeen2026-07-31T09:21:09.000ZCell and gene therapy manufacturers turn to specialist automation partnershttps://www.pharmaradar360.com/article/measures-from-the-adult-social-care-outcomes-framework-england-2025-to-2026-8bead6d4b132e9c4Pharma Surgeen2026-07-31T09:04:06.000ZMeasures from the adult social care outcomes framework, England: 2025 to 2026https://www.pharmaradar360.com/article/safeguarding-adults-england-2025-to-2026-report-5a1fde56716d266cPharma Surgeen2026-07-31T09:00:50.000ZSafeguarding adults, England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/deferred-payment-agreements-england-2025-to-2026-report-2caf38b8e49cf146Pharma Surgeen2026-07-31T08:58:04.000ZDeferred payment agreements, England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/adult-social-care-survey-england-2025-to-2026-report-9053469da7332a96Pharma Surgeen2026-07-31T08:49:13.000ZAdult social care survey, England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/healthy-child-programme-8d6d3d976dfbbf4fPharma Surgeen2026-07-31T08:30:07.000ZHealthy child programmehttps://www.pharmaradar360.com/article/care-continuity-between-midwifery-and-health-visiting-services-7052bd945725089cPharma Surgeen2026-07-31T08:30:04.000ZCare continuity between midwifery and health visiting serviceshttps://www.pharmaradar360.com/article/fda-regulatory-hurdles-expose-rare-disease-drug-crisis-b970ef9d24148159Pharma Surgeen2026-07-31T08:30:00.000ZFDA Regulatory Hurdles Expose Rare Disease Drug Crisishttps://www.pharmaradar360.com/article/unlocking-the-east-of-england-s-life-sciences-potential-reflections-from-our-reg-5210f7af0795e268Pharma Surgeen2026-07-31T08:29:55.000ZUnlocking the East of England’s life sciences potential: Reflections from our regional roundtablehttps://www.pharmaradar360.com/article/kosdaq-shift-to-ai-and-chips-hits-ingenia-therapeutics-ipo-demand-chosunbiz-780eca151a03e9ddPharma Surgeen2026-07-31T08:28:00.000ZKOSDAQ shift to AI and chips hits Ingenia Therapeutics IPO demand - CHOSUNBIZhttps://www.pharmaradar360.com/article/dhsc-spending-over-500-9d0eec9bf491adbdPharma Surgeen2026-07-31T08:23:03.000ZDHSC spending over £500https://www.pharmaradar360.com/article/dhsc-spending-over-500-june-2026-6a9f886019dc866cPharma Surgeen2026-07-31T08:22:59.000ZDHSC: spending over £500, June 2026https://www.pharmaradar360.com/article/dimensional-fund-advisors-lp-purchases-73-410-shares-of-teva-pharmaceutical-indu-51ad3d1262ce51caPharma Surgeen2026-07-31T08:13:52.000ZDimensional Fund Advisors LP Purchases 73,410 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/ono-pharmaceutical-profit-rose-despite-revenue-decline-driven-by-cost-cuts-and-o-f66830dc014a1c31Pharma Surgeen2026-07-31T08:09:44.000ZOno Pharmaceutical : Profit rose despite revenue decline, driven by cost cuts and overseas sales growthhttps://www.pharmaradar360.com/article/apnimed-s-ipo-dream-comes-true-with-upsized-192m-ipo-to-fund-sleep-apnea-pill-la-ffdc56d726c02f5dPharma Surgeen2026-07-31T08:09:06.000ZApnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launchhttps://www.pharmaradar360.com/article/b-riley-initiates-4d-molecular-therapeutics-stock-coverage-with-buy-rating-04e9dadbbb279687Pharma Surgeen2026-07-31T08:08:00.000ZB.Riley initiates 4D Molecular Therapeutics stock coverage with buy ratinghttps://www.pharmaradar360.com/article/the-ai-ready-factory-how-itot-integration-transforms-pharmaceutical-manufacturin-82aad78a3caff2ccPharma Surgeen2026-07-31T08:03:45.000ZThe AI-Ready Factory How ITOT Integration Transforms Pharmaceutical Manufacturing Data Into Actionable Intelligencehttps://www.pharmaradar360.com/article/sun-pharmaceutical-industries-shares-rise-2-03-in-today-s-session-5a04c8b677c45d35Pharma Surgeen2026-07-31T08:01:08.000ZSun Pharmaceutical Industries Shares Rise 2.03% in Today's Sessionhttps://www.pharmaradar360.com/article/mapping-ai-drug-discovery-the-companies-behind-biotech-s-most-searched-technolog-68c00e034de4829bPharma Surgeen2026-07-31T07:59:38.000ZMapping AI Drug Discovery: The Companies Behind Biotech’s Most-Searched Technologyhttps://www.pharmaradar360.com/article/eyepoint-completes-enrollment-of-duravyu-phase-3-trials-for-diabetic-macular-ede-018317361d37222bPharma Surgeen2026-07-31T07:37:59.000ZEyePoint Completes Enrollment of DURAVYU Phase 3 Trials for Diabetic Macular Edemahttps://www.pharmaradar360.com/article/selinexor-phase-3-trial-misses-primary-endpoint-in-endometrial-cancer-a285d71605c0e50fPharma Surgeen2026-07-31T07:37:59.000ZSelinexor Phase 3 Trial Misses Primary Endpoint in Endometrial Cancerhttps://www.pharmaradar360.com/article/latigo-s-ltg-001-phase-2b-data-signals-a-new-design-standard-for-nav1-8-pain-tri-6fc95c4eef6150a8Pharma Surgeen2026-07-31T07:37:59.000ZLatigo’s LTG-001 Phase 2b Data Signals a New Design Standard for NaV1.8 Pain Trialshttps://www.pharmaradar360.com/article/mid-day-exclusive-citizens-must-demand-standardised-food-inside-tukaram-mundhe-s-c6cdd620161a56bdPharma Surgeen2026-07-31T07:32:00.000ZMid-Day Exclusive | 'Citizens must demand standardised food': Inside Tukaram Mundhe's food safety crackdownhttps://www.pharmaradar360.com/article/press-release-on-il-sole-24-ore-interim-report-first-half-as-at-30-june-2026-5308b80c7823e971Pharma Surgeen2026-07-31T07:14:43.000ZPress release (on il Sole 24 Ore) – Interim Report First Half (as at 30 June 2026)https://www.pharmaradar360.com/article/how-krystal-biotech-inc-krys-affects-rotational-strategy-timing-8ed2e72870cc8b84Pharma Surgeen2026-07-31T07:10:02.000ZHow Krystal Biotech Inc. (KRYS) Affects Rotational Strategy Timinghttps://www.pharmaradar360.com/article/la-aemps-informa-sobre-la-restriccion-de-microplasticos-y-sus-implicaciones-para-33d7a5d38c312557Pharma Surgeen2026-07-31T07:00:28.000ZLa AEMPS informa sobre la restricción de microplásticos y sus implicaciones para los productos biocidas de su competenciahttps://www.pharmaradar360.com/article/prac-juli-2026-nieuwe-veiligheidsaanbevelingen-voor-anticonceptiemiddelen-met-de-67e2ec953abb2b0ePharma Surgeen2026-07-31T06:45:46.000ZPRAC juli 2026: nieuwe veiligheidsaanbevelingen voor anticonceptiemiddelen met desogestrel en etonogestrel en voor Litfulohttps://www.pharmaradar360.com/article/fda-agrees-single-phase-3-trial-sufficient-for-ath434-msa-approval-path-35014be2eac3110fPharma Surgeen2026-07-31T06:42:59.000ZFDA Agrees Single Phase 3 Trial Sufficient for ATH434 MSA Approval Pathhttps://www.pharmaradar360.com/article/mog-f8b87d67e31f27f3Pharma Surgeen2026-07-31T06:30:00.000Zエンスプリング、国内初の「MOG抗体関連疾患の再発予防」治療薬として適応拡大申請https://www.pharmaradar360.com/article/chugai-files-for-additional-indication-of-enspryng-as-japan-rsquo-s-potential-fi-8fb5f2c6035da10fPharma Surgeen2026-07-31T06:30:00.000ZChugai Files for Additional Indication of Enspryng as Japan&rsquo;s Potential First Treatment for Prevention of Relapse in MOG Antibody-associated Diseasehttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-stock-12-month-price-target-raised-to-19-4-eadb5dfe895ac37bPharma Surgeen2026-07-31T06:20:00.000ZTakeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $19.43, Implies 13% Upsidehttps://www.pharmaradar360.com/article/pfizer-seeks-label-expansion-for-litfulo-after-double-phase-iii-nsv-win-41a1049905c13ad9Pharma Surgeen2026-07-31T06:01:02.000ZPfizer seeks label expansion for Litfulo after double Phase III NSV winhttps://www.pharmaradar360.com/article/the-supreme-court-confirmed-the-ruling-that-cha-biotech-which-caused-the-stock-p-08b9850c0f54c50cPharma Surgeen2026-07-31T05:39:30.000ZThe Supreme Court confirmed the ruling that Cha Biotech, which caused the stock price crash by discl..https://www.pharmaradar360.com/article/teva-teva-stock-faces-earnings-shock-despite-strong-brand-growth-45eea88ab468e7efPharma Surgeen2026-07-31T05:37:39.000ZTeva (TEVA) Stock Faces Earnings Shock Despite Strong Brand Growthhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-maintained-at-neutral-by-major-u-s-securities-firm-target-cb3282f7773a0374Pharma Surgeen2026-07-31T05:35:00.000ZTakeda Pharmaceutical Maintained at "Neutral" by Major U.S. Securities Firm, Target Price Raised to ¥5,800https://www.pharmaradar360.com/article/new-certification-criteria-reshape-race-for-korea-s-innovative-pharma-company-ti-6362d5a33533bffdPharma Surgeen2026-07-31T05:12:00.000ZNew certification criteria reshape race for Korea’s 'innovative pharma company' titlehttps://www.pharmaradar360.com/article/egypt-highlights-health-reform-gains-calls-for-stronger-global-cooperation-again-894c79198b4f4807Pharma Surgeen2026-07-31T05:07:00.000ZEgypt highlights health reform gains, calls for stronger global cooperation against rising health threatshttps://www.pharmaradar360.com/article/fda-inspects-bombay-high-court-canteens-4103c7b8eca41614Pharma Surgeen2026-07-31T04:22:00.000ZFDA inspects Bombay High Court canteenshttps://www.pharmaradar360.com/article/cen-biotech-inc-revenue-breakdown-otc-cenbf-b80b7229ba8df14aPharma Surgeen2026-07-31T04:20:25.000ZCen Biotech, Inc. Revenue Breakdown – OTC:CENBFhttps://www.pharmaradar360.com/article/radiopharm-s-rad-101-hits-primary-endpoint-with-93-concordance-phase-3-trial-pla-be146d6e1eef8329Pharma Surgeen2026-07-31T04:14:41.000ZRadiopharm's RAD 101 Hits Primary Endpoint With 93% Concordance, Phase 3 Trial Planned for Q4 2026https://www.pharmaradar360.com/article/quality-affordability-and-innovation-define-india-s-pharma-success-pharmexcil-ch-5800a4de0bb35158Pharma Surgeen2026-07-31T04:10:19.000ZQuality, affordability and innovation define India's pharma success: PHARMEXCIL Chairman Namit Joshihttps://www.pharmaradar360.com/article/who-unveils-global-framework-to-accelerate-greener-pharmaceutical-regulation-7d239890c6769fe0Pharma Surgeen2026-07-31T04:05:42.000ZWHO Unveils Global Framework To Accelerate Greener Pharmaceutical Regulationhttps://www.pharmaradar360.com/article/we-re-in-india-have-to-take-realistic-approach-bombay-hc-restores-fda-suspended-92c7b7e62adc06d9Pharma Surgeen2026-07-31T04:01:45.000Z“We’re in India, Have to Take Realistic Approach”: Bombay HC Restores FDA-Suspended License of Navi Mumbai’s Park Inn by Radisson, Says Insects in Kitchen Can't Shut Down 4-Star Hotelhttps://www.pharmaradar360.com/article/handa-s-cancer-drug-wins-fda-tentative-approval-launch-possible-within-one-quart-c6e1316729ad463fPharma Surgeen2026-07-31T03:35:00.000ZHanda's Cancer Drug Wins FDA Tentative Approval, Launch Possible Within One Quarterhttps://www.pharmaradar360.com/article/ono-pharmaceutical-core-profit-rose-despite-lower-revenue-driven-by-royalties-an-0dab2491a6464469Pharma Surgeen2026-07-31T03:02:00.000ZOno Pharmaceutical : Core profit rose despite lower revenue, driven by royalties and overseas growthhttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-misight-1-day-bdaa9059666c384aPharma Surgeen2026-07-31T03:00:00.000Z[SHINSA]English Translation of Review Report: MiSight 1 Dayhttps://www.pharmaradar360.com/article/mumbai-latest-news-today-on-july-31st-2026-bhiwandi-collapse-fda-crackdown-drug-4efa6d67f2934cdfPharma Surgeen2026-07-31T02:51:15.000ZMumbai Latest News Today on July 31st, 2026: Bhiwandi Collapse, FDA Crackdown & Drug-Free Campaignhttps://www.pharmaradar360.com/article/shionogi-backed-biotech-apnimed-raises-192-million-in-us-ipo-a452df1f3acec29fPharma Surgeen2026-07-31T02:44:57.000ZShionogi-Backed Biotech Apnimed Raises $192 Million in US IPOhttps://www.pharmaradar360.com/article/legend-biotech-legn-ceo-exit-raises-questions-is-the-stock-still-cheap-19701e8a113b3507Pharma Surgeen2026-07-31T02:37:30.000ZLegend Biotech (LEGN) CEO Exit Raises Questions, Is The Stock Still Cheap?https://www.pharmaradar360.com/article/stocks-in-focus-takeda-pharmaceutical-declined-weighed-down-by-its-earnings-repo-d298f557926fc04fPharma Surgeen2026-07-31T02:29:47.000Z[Stocks in Focus] Takeda Pharmaceutical declined, weighed down by its earnings report; some analysts noted that it was 'left out of the spotlight' amid rising interest in AI-related stocks.https://www.pharmaradar360.com/article/fda-approves-first-oral-pcsk9-inhibitor-for-adults-with-high-cholesterol-9e4b38aa9eb19bc2Pharma Surgeen2026-07-31T02:15:00.000ZFDA approves first oral PCSK9 inhibitor for adults with high cholesterolhttps://www.pharmaradar360.com/article/after-celltrion-taisho-joins-kaigen-signs-japan-license-deal-for-fcrn-therapy-26213f699e02305aPharma Surgeen2026-07-31T02:12:19.000ZAfter Celltrion, Taisho Joins: Kaigen Signs Japan License Deal for FcRn Therapyhttps://www.pharmaradar360.com/article/us-tariffs-pose-threat-to-india-s-pharma-sector-f8ce9c78a3dfec7fPharma Surgeen2026-07-31T02:10:39.000ZUS tariffs pose threat to India's pharma sectorhttps://www.pharmaradar360.com/article/radiopharm-theranostics-advances-rad-101-toward-phase-3-after-strong-trial-resul-668b40054859b32ePharma Surgeen2026-07-31T01:48:20.000ZRadiopharm Theranostics Advances RAD 101 Toward Phase 3 After Strong Trial Resultshttps://www.pharmaradar360.com/article/biotech-growth-trust-plc-revenue-breakdown-aquisuk-biogl-8ec0c28aec1981bePharma Surgeen2026-07-31T01:02:42.000ZBiotech Growth Trust PLC Revenue Breakdown – AQUISUK:BIOGLhttps://www.pharmaradar360.com/article/kaigene-enters-into-exclusive-licensing-agreement-with-taisho-pharmaceutical-for-b3e2c6f4886e2455Pharma Surgeen2026-07-31T01:02:12.000ZKaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japanhttps://www.pharmaradar360.com/article/kaigene-enters-into-exclusive-licensing-agreement-with-taisho-pharmaceutical-for-6c9e7058dbc694a9Pharma Surgeen2026-07-31T01:01:00.000ZKaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japanhttps://www.pharmaradar360.com/article/hanmi-pyeongtaek-plant-secures-top-safety-grade-again-bolstering-korea-drug-outp-cfbc4a12d26ec355Pharma Surgeen2026-07-31T00:39:00.000ZHanmi Pyeongtaek plant secures top safety grade again, bolstering Korea drug output - CHOSUNBIZhttps://www.pharmaradar360.com/article/three-s-an-ipo-crowd-biotech-trio-set-to-raise-575m-in-total-c74733d740d527afPharma Surgeen2026-07-31T00:11:36.000ZThree's an IPO crowd: biotech trio set to raise $575M in totalhttps://www.pharmaradar360.com/article/kpti-looks-18-2-overvalued-on-gf-valuetm-after-phase-3-trial-set-061fe27f53252254Pharma Surgeen2026-07-31T00:08:14.000ZKPTI Looks 18.2% Overvalued on GF Value™ After Phase 3 Trial Sethttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-e0b56db8d6e733a6Pharma Surgeen2026-07-31T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-b038682c2a8e0471Pharma Surgeen2026-07-31T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/moderna-filed-form-8-k-c57db27759d2ed88Pharma Surgeen2026-07-31T00:00:00.000ZModerna filed Form 8-Khttps://www.pharmaradar360.com/article/abbvie-filed-form-8-k-0aa5171de0c622b6Pharma Surgeen2026-07-31T00:00:00.000ZAbbVie filed Form 8-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-3c395c9e358285cbPharma Surgeen2026-07-31T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-b4d5895a01e246f3Pharma Surgeen2026-07-31T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-11155bd03648139fPharma Surgeen2026-07-31T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-d8b3190f9c337cd2Pharma Surgeen2026-07-31T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-13423e8b711e9c15Pharma Surgeen2026-07-31T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-bc7d251a592191b7Pharma Surgeen2026-07-31T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-7a111ec7b035d9d5Pharma Surgeen2026-07-31T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-4dd00df478664b27Pharma Surgeen2026-07-31T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-71c89adfc6e83408Pharma Surgeen2026-07-31T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-333a8b5d061f0604Pharma Surgeen2026-07-31T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-5323b6eadda0a1bbPharma Surgeen2026-07-31T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-01a3891e6e1ad3a1Pharma Surgeen2026-07-31T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-5662f346ca27e51bPharma Surgeen2026-07-31T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-c495d8069c88431ePharma Surgeen2026-07-31T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/medicare-program-fy-2027-inpatient-psychiatric-facilities-prospective-payment-sy-8950715721a572b0Pharma Surgeen2026-07-31T00:00:00.000ZMedicare Program; FY 2027 Inpatient Psychiatric Facilities Prospective Payment System-Rate Updatehttps://www.pharmaradar360.com/article/reducing-bureaucracy-and-burden-for-family-assistance-programs-708ce48d8a8f5576Pharma Surgeen2026-07-31T00:00:00.000ZReducing Bureaucracy and Burden for Family Assistance Programshttps://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-data-use-certification-for-the-nih-br-4723a27aa281ac65Pharma Surgeen2026-07-31T00:00:00.000ZProposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)https://www.pharmaradar360.com/article/medicare-program-prospective-payment-system-and-consolidated-billing-for-skilled-cfeb0d49ed2b43bcPharma Surgeen2026-07-31T00:00:00.000ZMedicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program for Federal Fiscal Year 2027https://www.pharmaradar360.com/article/national-center-for-complementary-and-integrative-health-amended-notice-of-meeti-d1def6219c9f646dPharma Surgeen2026-07-31T00:00:00.000ZNational Center for Complementary and Integrative Health; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-cb28c7535db85db0Pharma Surgeen2026-07-31T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meeting-69da69980676912dPharma Surgeen2026-07-31T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-46a7e6261d9ead5cPharma Surgeen2026-07-31T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/office-of-the-secretary-notice-of-meeting-b5e8830e611f6667Pharma Surgeen2026-07-31T00:00:00.000ZOffice of the Secretary; Notice of Meetinghttps://www.pharmaradar360.com/article/drug-label-update-sugammadex-588214b5a2f10737Pharma Surgeen2026-07-31T00:00:00.000ZDrug label update: Sugammadexhttps://www.pharmaradar360.com/article/drug-label-update-dehydrated-alcohol-4de2a9d54f6767d5Pharma Surgeen2026-07-31T00:00:00.000ZDrug label update: Dehydrated Alcoholhttps://www.pharmaradar360.com/article/pharmacologic-treatment-response-in-panic-disorder-with-comorbid-medical-conditi-f6b2eedc667a4939Pharma Surgeen2026-07-31T00:00:00.000ZPharmacologic Treatment Response in Panic Disorder with Comorbid Medical Conditions: A Systematic and Narrative Reviewhttps://www.pharmaradar360.com/article/drug-induced-immunomodulation-and-healthcare-associated-infection-risk-in-nigeri-dde7a106e56a5866Pharma Surgeen2026-07-31T00:00:00.000ZDrug-Induced Immunomodulation and Healthcare-Associated Infection Risk in Nigerian Trauma Intensive Care Units: A Narrative Reviewhttps://www.pharmaradar360.com/article/feasibility-study-of-a-novel-mhealth-clinical-decision-support-application-to-en-8b5b7211ab3e0fa3Pharma Surgeen2026-07-31T00:00:00.000ZFeasibility study of a novel mHealth clinical decision support application to enable community health workers to manage hypertension in rural Guatemalahttps://www.pharmaradar360.com/article/socio-demographic-and-clinical-profile-of-autism-spectrum-disorder-in-children-a-c203e65c7b8052e4Pharma Surgeen2026-07-31T00:00:00.000ZSocio-Demographic and Clinical Profile of Autism Spectrum Disorder in Children Attending a Tertiary Care Hospital: A Study of 100 Caseshttps://www.pharmaradar360.com/article/microfluidic-t-chip-enables-one-step-clinical-scale-t-cell-purification-from-blo-0f5085ef6dbfaf1aPharma Surgeen2026-07-31T00:00:00.000ZMicrofluidic T-Chip enables one-step clinical-scale T-cell purification from blood products for CAR T-cell manufacturinghttps://www.pharmaradar360.com/article/an-integrated-data-cleaning-and-anomaly-detection-pipeline-for-improving-clinica-954e16ee43b132dcPharma Surgeen2026-07-31T00:00:00.000ZAn Integrated Data Cleaning and Anomaly Detection Pipeline for Improving Clinical Data Quality in Primary Healthcarehttps://www.pharmaradar360.com/article/pancreatic-and-periampullary-cancer-surgery-early-outcomes-and-clinical-implicat-7992487a6d4732f0Pharma Surgeen2026-07-31T00:00:00.000ZPancreatic and Periampullary Cancer Surgery: Early Outcomes and Clinical Implications from a Single-Center Experiencehttps://www.pharmaradar360.com/article/bruylant-s-test-for-2-2-bimorphine-020e738d32f016efPharma Surgeen2026-07-31T00:00:00.000ZBruylant’s test for 2,2’-bimorphinehttps://www.pharmaradar360.com/article/synthesis-characterization-and-antibacterial-activity-of-benzimidazole-schiff-ba-64bd8a674dc96a12Pharma Surgeen2026-07-31T00:00:00.000ZSynthesis, characterization, and antibacterial activity of Benzimidazole Schiff Bases and Bis(thiazolidin-4-one) Derivativeshttps://www.pharmaradar360.com/article/synthesis-characterization-and-antioxidant-activity-of-pt-ii-and-pd-ii-dithiocar-aeeb5f082c881e2dPharma Surgeen2026-07-31T00:00:00.000ZSynthesis, Characterization, and Antioxidant Activity of Pt (II) and Pd (II) Dithiocarbamate Complexes Derived from 4-Methyl-2-phenylpiperazine and 4-Phenylpiperazine with and without 1,2-Bis(diphenylphosphino)ethanehttps://www.pharmaradar360.com/article/reconstruction-of-distal-amputation-of-the-right-index-finger-using-a-kutler-fla-3aa51ebd5b266fdbPharma Surgeen2026-07-31T00:00:00.000ZReconstruction of Distal Amputation of the Right Index Finger Using a Kutler Flap: A Case Reporthttps://www.pharmaradar360.com/article/gallstone-ileus-caused-by-a-cholecystoduodenal-fistula-in-a-58-year-old-man-a-ca-dd36fc84b4605c06Pharma Surgeen2026-07-31T00:00:00.000ZGallstone Ileus Caused by A Cholecystoduodenal Fistula in A 58-Year-Old Man: A Case Reporthttps://www.pharmaradar360.com/article/incidental-perioperative-detection-of-congenital-methemoglobinemia-a-prospective-65fcd64397ff3896Pharma Surgeen2026-07-31T00:00:00.000ZIncidental perioperative detection of congenital methemoglobinemia: A prospective case series from a South Indian referral centrehttps://www.pharmaradar360.com/article/beyond-infections-clinical-and-genetic-spectrum-of-pediatric-immune-dysregulatio-c2dd7c04d28cd178Pharma Surgeen2026-07-31T00:00:00.000ZBeyond Infections: Clinical and Genetic Spectrum of Pediatric Immune Dysregulation Disordershttps://www.pharmaradar360.com/article/intracameral-steroids-in-pediatric-cataract-surgery-clinical-insights-and-the-ro-d578ee729b069e5bPharma Surgeen2026-07-31T00:00:00.000ZIntracameral steroids in pediatric cataract surgery: Clinical insights and the road ahead for sustained drug deliveryhttps://www.pharmaradar360.com/article/clinical-profile-and-perioperative-risk-factors-for-post-cataract-surgery-nonart-dd9bd3cb6a90ec1bPharma Surgeen2026-07-31T00:00:00.000ZClinical profile and perioperative risk factors for post-cataract surgery nonarteritic anterior ischemic optic neuropathy in an Indian population: An emulated target trialhttps://www.pharmaradar360.com/article/wearable-cardioverter-defibrillator-in-clinical-practice-what-we-know-and-what-q-9f55d7e818401294Pharma Surgeen2026-07-31T00:00:00.000ZWearable cardioverter-defibrillator in clinical practice — what we know and what questions are still to be answeredhttps://www.pharmaradar360.com/article/reevaluating-heart-transplant-compatibility-a-retrospective-analysis-using-echoc-796843a4b7526a0bPharma Surgeen2026-07-31T00:00:00.000ZReevaluating Heart Transplant Compatibility: A Retrospective Analysis Using Echocardiographic Left Ventricular Mass Matchinghttps://www.pharmaradar360.com/article/retroperitoneal-renal-surgery-with-the-hugotm-ras-system-feasibility-setting-and-ba798b494fda94d8Pharma Surgeen2026-07-31T00:00:00.000ZRetroperitoneal Renal Surgery with the Hugo™ RAS System: Feasibility, Setting and Perioperative Outcomes of the First Dedicated Serieshttps://www.pharmaradar360.com/article/machine-learning-based-prediction-of-cervical-pedicle-screw-malposition-from-cli-71724bc124c90b56Pharma Surgeen2026-07-31T00:00:00.000ZMachine-Learning-Based Prediction of Cervical Pedicle Screw Malposition from Clinical and Anatomical Featureshttps://www.pharmaradar360.com/article/explainable-clinical-decision-support-for-metabolic-index-prediction-in-gout-pat-f0a0e24860ca5683Pharma Surgeen2026-07-31T00:00:00.000ZExplainable Clinical Decision Support for Metabolic Index Prediction in Gout Patients Using GA-Optimized Ensemble Learning Modelshttps://www.pharmaradar360.com/article/autologous-cutis-and-subcutis-micrografts-combined-with-a-collagen-elastin-derma-5c706009001b232cPharma Surgeen2026-07-31T00:00:00.000ZAutologous cutis and subcutis micrografts combined with a collagen–elastin dermal scaffold for chronic wounds: a retrospective single-arm clinical study with prospectively collected datahttps://www.pharmaradar360.com/article/model-based-clinical-utility-of-pharmacogenetic-testing-and-its-potential-popula-544c28a47bed54dcPharma Surgeen2026-07-31T00:00:00.000ZModel-based clinical utility of pharmacogenetic testing and its potential population impact on the use of essential medicines in Zimbabwehttps://www.pharmaradar360.com/article/correlation-between-the-cd8-t-cell-ifn-axis-and-clinical-disease-progression-at-5680fde7dd190c7ePharma Surgeen2026-07-31T00:00:00.000ZCorrelation between the CD8+ T cell/IFN-γ axis and clinical disease progression at different phases of ITPhttps://www.pharmaradar360.com/article/prevalence-and-multilevel-factors-associated-with-clinical-breast-examination-up-ea17d984e481572cPharma Surgeen2026-07-31T00:00:00.000ZPrevalence and multilevel factors associated with clinical breast examination uptake among women in sub-Saharan Africa: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/dietary-linolenic-acid-improves-skin-blood-flow-following-cold-exposure-and-endo-3baf769d9e390b91Pharma Surgeen2026-07-31T00:00:00.000ZDietary α-linolenic acid improves skin blood flow following cold exposure and endothelial function in healthy adults: a randomized, double-blind, placebo-controlled, parallel-group comparative trialhttps://www.pharmaradar360.com/article/artificial-intelligence-and-telemedicine-integration-in-managing-in-flight-medic-7ab9292a789fe09ePharma Surgeen2026-07-31T00:00:00.000ZArtificial Intelligence and telemedicine integration in managing in-flight medical emergencies: Current evidence, clinical applications and future directionshttps://www.pharmaradar360.com/article/clinical-and-tomographic-features-of-a-presumed-macular-corneal-dystrophy-in-a-m-7f4bb3ac0ee2480ePharma Surgeen2026-07-31T00:00:00.000ZClinical and tomographic features of a presumed macular corneal dystrophy in a Moroccan sibling cohorthttps://www.pharmaradar360.com/article/the-evolving-profile-of-herpes-zoster-outpatients-a-literature-review-of-socio-d-8d5e8bc161b772b4Pharma Surgeen2026-07-31T00:00:00.000ZThe evolving profile of herpes zoster outpatients: A literature review of socio-demographics, comorbidities, and clinical manifestationshttps://www.pharmaradar360.com/article/clinical-characteristics-and-treatment-response-of-infantile-hemangioma-patients-2c54ff2963790b6ePharma Surgeen2026-07-31T00:00:00.000ZClinical characteristics and treatment response of infantile hemangioma patients treated with oral propranololhttps://www.pharmaradar360.com/article/stratified-analysis-of-socioeconomic-status-hypertension-burden-and-drug-complia-a5cb31c5ef2e5d41Pharma Surgeen2026-07-31T00:00:00.000ZStratified analysis of socioeconomic status, hypertension burden and drug compliance in South-Eastern Nigeriahttps://www.pharmaradar360.com/article/examine-the-impact-of-mesenchymal-stem-cells-on-corneal-healing-via-clinical-and-cd8979e8cfea317cPharma Surgeen2026-07-31T00:00:00.000ZExamine the impact of mesenchymal stem cells on corneal healing via clinical and molecular researchhttps://www.pharmaradar360.com/article/monitoring-the-organic-enrichment-and-the-trophic-status-of-the-aquatic-environm-e9b561567b6a0ef5Pharma Surgeen2026-07-31T00:00:00.000ZMonitoring the organic enrichment and the trophic status of the aquatic environment beneath a long-line system of Mediterranean mussel culturehttps://www.pharmaradar360.com/article/antioxidant-activity-and-quantification-of-phenolic-compounds-in-methanolic-extr-a80f1f5989c6b6acPharma Surgeen2026-07-31T00:00:00.000ZAntioxidant activity and quantification of phenolic compounds in methanolic extract of Origanum majorana L.https://www.pharmaradar360.com/article/quantitative-endocannabinoid-profiling-a-systems-biology-framework-for-natural-m-0c4c550bd35e3e96Pharma Surgeen2026-07-31T00:00:00.000ZQuantitative endocannabinoid profiling: A systems biology framework for natural medicine researchhttps://www.pharmaradar360.com/article/epidemiology-clinical-characteristics-and-outcomes-of-patients-with-severe-traum-a2d4e6606b50b049Pharma Surgeen2026-07-31T00:00:00.000ZEpidemiology, clinical characteristics and outcomes of patients with severe traumatic brain injury treated by emergency medical services in New Zealand: a retrospective observational studyhttps://www.pharmaradar360.com/article/the-evolution-of-the-treadmill-test-in-cardiology-from-clinical-observation-to-a-ae08429d761d6b9ePharma Surgeen2026-07-31T00:00:00.000ZThe evolution of the treadmill test in cardiology: from clinical observation to a global standard of functional diagnosticshttps://www.pharmaradar360.com/article/therapeutic-potential-of-talahridaya-marma-in-cardiovascular-homeostasis-a-clini-2a96b835ed541003Pharma Surgeen2026-07-31T00:00:00.000ZTherapeutic Potential of Talahridaya Marma in Cardiovascular Homeostasis: A Clinical Reviewhttps://www.pharmaradar360.com/article/medilink-a-secure-role-based-healthcare-management-platform-with-integrated-rule-d5a9af8aff75273cPharma Surgeen2026-07-31T00:00:00.000ZMediLink: A Secure Role-Based Healthcare Management Platform with Integrated Rule-Based Clinical Decision Support and Multilingual Voice Interactionhttps://www.pharmaradar360.com/article/cross-modal-deep-learning-framework-for-multi-disease-risk-assessment-using-clin-2ceb7f72c8ec3244Pharma Surgeen2026-07-31T00:00:00.000ZCross-Modal Deep Learning Framework for Multi-Disease Risk Assessment Using Clinical Data and Medical Imageshttps://www.pharmaradar360.com/article/clinical-text-mining-with-bert-for-lung-cancer-prognosis-a-comparative-survival-d102bca8fa735123Pharma Surgeen2026-07-31T00:00:00.000ZClinical Text Mining with BERT for Lung Cancer Prognosis: A Comparative Survival Analysishttps://www.pharmaradar360.com/article/prevalence-associated-factors-and-clinical-outcomes-of-atrial-fibrillation-among-ace139ba463a647cPharma Surgeen2026-07-31T00:00:00.000ZPrevalence, associated factors and clinical outcomes of atrial fibrillation among acute stroke patients in Mwanza, Tanzania. A cross-section studyhttps://www.pharmaradar360.com/article/video-based-markerless-motion-capture-for-clinical-and-rehabilitation-biomechani-78ddee2082259807Pharma Surgeen2026-07-31T00:00:00.000ZVideo-Based Markerless Motion Capture for Clinical and Rehabilitation Biomechanics: A PRISMA-ScR Scoping Review of Validated Architectures, Clinical Readiness, and Emerging Methodshttps://www.pharmaradar360.com/article/use-of-a-vessel-sealing-device-during-elective-orchiectomy-in-client-owned-pet-r-05428d6ca2abd742Pharma Surgeen2026-07-31T00:00:00.000ZUse of a Vessel Sealing Device During Elective Orchiectomy in Client-Owned Pet Rabbits: A Clinical Comparison with Conventional Ligationhttps://www.pharmaradar360.com/article/machine-learning-prediction-of-postoperative-pain-improvement-following-coronary-74ed49f40817d6b2Pharma Surgeen2026-07-31T00:00:00.000ZMachine Learning Prediction of Postoperative Pain Improvement Following Coronary Artery Bypass Grafting Using Preoperative Clinical, Psychosocial, Fatigue, and Functional Variableshttps://www.pharmaradar360.com/article/face-to-face-cognitive-behavioral-therapy-versus-metacognitive-informed-app-base-335cc7db67b828b4Pharma Surgeen2026-07-31T00:00:00.000ZFace-to-Face Cognitive-Behavioral Therapy Versus Metacognitive-Informed App-Based Digital Intervention Versus Their Combination in Adults with Chronic Pain: A Three-Arm Randomized Controlled Trialhttps://www.pharmaradar360.com/article/a-psychoanalytic-inquiry-into-the-pastoral-counselor-s-good-shepherd-complex-foc-1eee533b4f841b3cPharma Surgeen2026-07-31T00:00:00.000ZA Psychoanalytic Inquiry into the Pastoral Counselor’s ‘Good Shepherd Complex’ — Focusing on the Reconfiguration of the Counselor’s Goodwill and Clinical Responsibilityhttps://www.pharmaradar360.com/article/rhinoconjunctivitis-and-probable-bronchial-asthma-due-to-sensitization-to-transg-ba80da1a35f801c4Pharma Surgeen2026-07-31T00:00:00.000ZRhinoconjunctivitis and Probable Bronchial Asthma Due to Sensitization to Transglutaminasehttps://www.pharmaradar360.com/article/nutritional-support-for-critically-ill-patients-by-the-korean-society-for-parent-04104f5d1ff12cfdPharma Surgeen2026-07-31T00:00:00.000ZNutritional support for critically ill patients by the Korean Society for Parenteral and Enteral Nutrition—part II: a clinical practice guidelinehttps://www.pharmaradar360.com/article/mechanistic-insights-clinical-significance-and-management-strategies-for-postgas-8386d5ace0962561Pharma Surgeen2026-07-31T00:00:00.000ZMechanistic insights, clinical significance, and management strategies for postgastrectomy hypoglycemia in gastric cancer patients in the era of continuous glucose monitoring: a narrative reviewhttps://www.pharmaradar360.com/article/noninvasive-brain-stimulation-for-parkinson-s-disease-therapeutic-applications-a-55032b1b1ca66c3bPharma Surgeen2026-07-31T00:00:00.000ZNoninvasive Brain Stimulation for Parkinson’s Disease: Therapeutic Applications and Clinical Perspectiveshttps://www.pharmaradar360.com/article/adoption-of-decentralized-clinical-trial-terminology-a-systematic-review-of-self-e38770ee916e8f5cPharma Surgeen2026-07-31T00:00:00.000ZAdoption of ‘decentralized’ clinical trial terminology: a systematic review of self-identified decentralized clinical trialshttps://www.pharmaradar360.com/article/mucormycosis-in-critically-ill-patients-a-9-year-multicenter-cohort-study-of-cli-f53bb2210a394cabPharma Surgeen2026-07-31T00:00:00.000ZMucormycosis in critically ill patients: a 9-year multicenter cohort study of clinical features, management, and 90-day outcomeshttps://www.pharmaradar360.com/article/clinical-neuroimaging-and-genetic-analyses-of-isolated-sulfite-oxidase-deficienc-93a10b9635f6793aPharma Surgeen2026-07-31T00:00:00.000ZClinical, neuroimaging, and genetic analyses of isolated sulfite oxidase deficiency in Chinese neonates: a retrospective case series with a narrative synthesis of previously reported caseshttps://www.pharmaradar360.com/article/impact-of-neuromuscular-and-visuo-motor-training-on-landing-biomechanics-functio-8245f9e3d72cb863Pharma Surgeen2026-07-31T00:00:00.000ZImpact of neuromuscular and visuo-motor training on landing biomechanics, functional performance, and psychological factors in female athletes with unilateral anterior cruciate ligament reconstruction: a simple parallel-group randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-profile-of-dengue-patients-presenting-with-epistaxis-at-a-tertiary-hosp-6312280f80cd5650Pharma Surgeen2026-07-31T00:00:00.000ZClinical profile of dengue patients presenting with epistaxis at a tertiary hospital in Kathmandu, Nepalhttps://www.pharmaradar360.com/article/clinical-characteristics-diagnostic-challenges-and-management-of-pulmonary-actin-2f0e19a29e56936dPharma Surgeen2026-07-31T00:00:00.000ZClinical characteristics, diagnostic challenges, and management of pulmonary actinomycosis: a 10-year retrospective cohort studyhttps://www.pharmaradar360.com/article/propofol-for-palliative-sedation-a-systematic-review-of-clinical-outcomes-safety-7eeb708a931faa0ePharma Surgeen2026-07-31T00:00:00.000ZPropofol for palliative sedation: A systematic review of clinical outcomes, safety, and ethical implicationshttps://www.pharmaradar360.com/article/tricuspid-valve-regurgitation-following-stylet-lumen-less-active-fixation-lead-o-5b9208b04daf9be6Pharma Surgeen2026-07-31T00:00:00.000ZTricuspid Valve Regurgitation Following Stylet Lumen‐Less Active Fixation Lead or Leadless Pacemaker Implantationhttps://www.pharmaradar360.com/article/addressing-health-literacy-by-school-nurses-at-schools-across-germany-results-of-c9f065ca4931c73fPharma Surgeen2026-07-31T00:00:00.000ZAddressing Health Literacy by School Nurses at Schools Across Germany: Results of a Mixed‐Methods Studyhttps://www.pharmaradar360.com/article/preferences-of-stroke-survivors-for-mental-health-service-a-discrete-choice-expe-c6706a04c464350dPharma Surgeen2026-07-31T00:00:00.000ZPreferences of Stroke Survivors for Mental Health Service: A Discrete Choice Experimenthttps://www.pharmaradar360.com/article/cutaneous-t-cell-lymphoma-and-dupilumab-for-atopic-dermatitis-practical-guidance-392f5f4f75cd4650Pharma Surgeen2026-07-31T00:00:00.000ZCutaneous T‐cell lymphoma and dupilumab for atopic dermatitis: Practical guidance for a clinical conundrumhttps://www.pharmaradar360.com/article/patient-reported-outcome-measures-and-clinical-performance-in-hemophilia-implica-cc9bf4d8aa11f657Pharma Surgeen2026-07-31T00:00:00.000ZPatient‐Reported Outcome Measures and Clinical Performance in Hemophilia: Implications for Person‐Centered Carehttps://www.pharmaradar360.com/article/comment-on-advancing-geriatric-care-in-japan-integrating-the-scp-5ms-scp-framewo-e9a837f1e47c9022Pharma Surgeen2026-07-31T00:00:00.000ZComment on “Advancing Geriatric Care in Japan: Integrating the <scp>5Ms</scp> Framework With Comprehensive Geriatric Assessment for Enhanced Clinical Practice in a Super‐Aged Society”https://www.pharmaradar360.com/article/comment-on-clinical-characteristics-and-prognosis-of-thromboembolism-in-elderly-e2e380217d768f7aPharma Surgeen2026-07-31T00:00:00.000ZComment on “Clinical Characteristics and Prognosis of Thromboembolism in Elderly Patients With Stage <scp>IV</scp> Lung Cancer”https://www.pharmaradar360.com/article/scp-i-cyp2c19-i-scp-c-scp-681g-scp-gt-a-is-not-in-complete-linkage-disequilibriu-d01f3623cd9e8fcaPharma Surgeen2026-07-31T00:00:00.000Z<scp> <i>CYP2C19</i> </scp> c. <scp>681G</scp> &gt;A Is not in Complete Linkage Disequilibrium With c.332‐ <scp>23A</scp> &gt;G: Implications for Pharmacogenetic Testinghttps://www.pharmaradar360.com/article/efficacy-and-safety-of-alpha-lipoic-acid-as-an-adjunctive-therapy-in-schizophren-65040be75b4ba5bePharma Surgeen2026-07-31T00:00:00.000ZEfficacy and Safety of Alpha-Lipoic Acid as an Adjunctive Therapy in Schizophreniahttps://www.pharmaradar360.com/article/development-of-a-high-content-stem-cell-focused-drug-screening-platform-for-i-sc-dcb8662964a99ba0Pharma Surgeen2026-07-31T00:00:00.000ZDevelopment of a High-Content Stem Cell Focused Drug Screening Platform for <i>Schistosoma mansoni</i> Using Developmentally Advanced Liver Schistosomula - Functional Insights and New Protein Target Leadshttps://www.pharmaradar360.com/article/physical-activity-and-sitting-over-9-years-of-the-women-s-health-initiative-stro-ff91189669f4a4dcPharma Surgeen2026-07-31T00:00:00.000ZPhysical Activity and Sitting over 9 years of the Women’s Health Initiative Strong &amp; Healthy ( <i>WHISH</i> ) Randomized Physical Activity Intervention Trial in Older Womenhttps://www.pharmaradar360.com/article/the-role-and-clinical-significance-of-the-mir-378a-3p-mapk1-axis-in-hypertensive-fceffe1a6f3bd1acPharma Surgeen2026-07-31T00:00:00.000ZThe role and clinical significance of the miR‑378a‑3p/MAPK1 axis in hypertensive vascular remodelinghttps://www.pharmaradar360.com/article/protection-at-the-margins-92e911c538a67d3fPharma Surgeen2026-07-31T00:00:00.000ZProtection at the Marginshttps://www.pharmaradar360.com/article/efficacy-and-evidential-quality-of-antioxidant-supplementation-in-human-sperm-pr-98f57a5b88a696e2Pharma Surgeen2026-07-31T00:00:00.000ZEfficacy and Evidential Quality of Antioxidant Supplementation in Human Sperm Processing Media: A Scoping Reviewhttps://www.pharmaradar360.com/article/from-fungicide-to-phagosome-a-one-health-view-of-copper-driven-fungal-bacterial-7e3e2a6576cc07c8Pharma Surgeen2026-07-31T00:00:00.000ZFrom Fungicide to Phagosome: A One Health View of Copper-Driven Fungal–Bacterial Interactionshttps://www.pharmaradar360.com/article/regimen-simplification-in-mdr-rr-tb-following-the-prospect-trial-a8135c9a292c04b7Pharma Surgeen2026-07-31T00:00:00.000ZRegimen simplification in MDR/RR-TB following the PROSPECT trialhttps://www.pharmaradar360.com/article/fibroblast-growth-factor-receptor-signaling-in-head-and-neck-tumors-molecular-pa-fb7419303492a700Pharma Surgeen2026-07-31T00:00:00.000ZFibroblast growth factor receptor signaling in head and neck tumors: molecular pathogenesis and potential therapeutic targetshttps://www.pharmaradar360.com/article/deciphering-the-mechanistic-landscape-of-notch-signaling-in-autoimmune-pathogene-96262ea659c15032Pharma Surgeen2026-07-31T00:00:00.000ZDeciphering the mechanistic landscape of notch signaling in autoimmune pathogenesishttps://www.pharmaradar360.com/article/klinik-und-diagnostik-mastzellvermittelter-angioodeme-9939582bcc16e13cPharma Surgeen2026-07-31T00:00:00.000ZKlinik und Diagnostik mastzellvermittelter Angioödemehttps://www.pharmaradar360.com/article/iot-xai-fusion-for-smart-and-transparent-clinical-decision-support-systems-311bbf08666530eePharma Surgeen2026-07-31T00:00:00.000ZIoT-XAI Fusion for Smart and Transparent Clinical Decision Support Systemshttps://www.pharmaradar360.com/article/mortality-related-to-different-circulatory-diseases-before-during-and-after-the-b51d60447e2f6ee3Pharma Surgeen2026-07-31T00:00:00.000ZMortality Related to Different Circulatory Diseases Before, During and After the COVID‐19 Pandemichttps://www.pharmaradar360.com/article/mobile-health-interventions-to-improve-adherence-to-oral-anticoagulant-treatment-9d8a75516ba583fbPharma Surgeen2026-07-31T00:00:00.000ZMobile health interventions to improve adherence to oral anticoagulant treatment: A systematic review and critical analysishttps://www.pharmaradar360.com/article/influence-of-fish-skin-i-labeo-rohita-i-and-chia-seed-oil-i-salvia-hispanica-i-b-0d025d0cb6abe8dfPharma Surgeen2026-07-31T00:00:00.000ZInfluence of Fish Skin ( <i>Labeo rohita</i> ) and Chia Seed Oil ( <i>Salvia hispanica</i> ) Blend on the Protein‐Rich Breakfast Cereal Product Made Through the Use of Whole and Modified Chia Flour and Fish Skin Protein Isolateshttps://www.pharmaradar360.com/article/nanoporous-silica-embedded-in-nanoporous-platinum-a-versatile-composite-coating-f60452433efd45f5Pharma Surgeen2026-07-31T00:00:00.000ZNanoporous Silica Embedded in Nanoporous Platinum: A Versatile Composite Coating for Implant‐Associated Drug Delivery From Neuronal Electrodeshttps://www.pharmaradar360.com/article/digital-cognitive-testing-in-mitochondrial-disease-validity-and-challenges-for-c-c24000a04d3c1e0fPharma Surgeen2026-07-31T00:00:00.000ZDigital Cognitive Testing in Mitochondrial Disease: Validity and Challenges for Clinical Trial Usehttps://www.pharmaradar360.com/article/nct07739602-effects-of-cornelian-cherry-supplementation-in-patients-with-metabol-87fbc894d7323759Pharma Surgeen2026-07-31T00:00:00.000ZNCT07739602: Effects of Cornelian Cherry Supplementation in Patients With Metabolic Syndromehttps://www.pharmaradar360.com/article/nct07739511-paclitaxel-oral-solution-in-her2-positive-breast-cancer-neoadjuvant-685a12891a050f5fPharma Surgeen2026-07-31T00:00:00.000ZNCT07739511: Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Studyhttps://www.pharmaradar360.com/article/nct07738692-effects-of-various-types-of-ultrasound-therapy-in-knee-osteoarthriti-663ebea7a6dc1083Pharma Surgeen2026-07-31T00:00:00.000ZNCT07738692: Effects of Various Types of Ultrasound Therapy in Knee Osteoarthritishttps://www.pharmaradar360.com/article/nct07738315-elemene-liposomes-in-endometrial-cancer-eff8a9cccfc229f5Pharma Surgeen2026-07-31T00:00:00.000ZNCT07738315: Elemene Liposomes in Endometrial Cancerhttps://www.pharmaradar360.com/article/nct07730177-challenge-trial-of-pfspz-larc2-vaccine-in-burkina-faso-55441280b3fab9b4Pharma Surgeen2026-07-31T00:00:00.000ZNCT07730177: Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Fasohttps://www.pharmaradar360.com/article/nct07673900-semaglutide-delivered-epi-intradermally-by-microarray-patch-vx-201-v-189617294ee789ffPharma Surgeen2026-07-31T00:00:00.000ZNCT07673900: Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participantshttps://www.pharmaradar360.com/article/nct07669077-a-study-to-assess-nipocalimab-concentrations-in-breast-milk-of-healt-59b2adcda68288f6Pharma Surgeen2026-07-31T00:00:00.000ZNCT07669077: A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating Womenhttps://www.pharmaradar360.com/article/nct07650799-ai-assisted-rare-disease-diagnosis-baba422575fc1faePharma Surgeen2026-07-31T00:00:00.000ZNCT07650799: AI-assisted Rare Disease Diagnosishttps://www.pharmaradar360.com/article/nct07640802-psychotherapy-for-irritability-in-youth-comparing-active-treatment-t-7d4264b318da1809Pharma Surgeen2026-07-31T00:00:00.000ZNCT07640802: Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapyhttps://www.pharmaradar360.com/article/nct07581002-a-study-to-assess-adverse-events-and-change-in-disease-activity-when-f12d5feede29ceffPharma Surgeen2026-07-31T00:00:00.000ZNCT07581002: A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)https://www.pharmaradar360.com/article/nct07559136-a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pha-0f6782bc7fb4e39fPharma Surgeen2026-07-31T00:00:00.000ZNCT07559136: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesityhttps://www.pharmaradar360.com/article/nct07536308-a-safety-and-immunogenicity-trial-of-ocu500-chad36-vector-encoding-s-0e8a6e59eb441be3Pharma Surgeen2026-07-31T00:00:00.000ZNCT07536308: A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adultshttps://www.pharmaradar360.com/article/nct07512128-study-of-the-shockwave-medical-skyrunner-carotid-intravascular-litho-79d4286066c4db43Pharma Surgeen2026-07-31T00:00:00.000ZNCT07512128: Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Femoral Stenting (SKYWARD Trans-Femoral IDE [Investigational Device Exemption] Study)https://www.pharmaradar360.com/article/nct07421570-the-effect-of-capacitive-and-resistive-electrical-transfer-therapy-o-56b3cc6a917f4e61Pharma Surgeen2026-07-31T00:00:00.000ZNCT07421570: The Effect of Capacitive and Resistive Electrical Transfer Therapy on Hamstring Injurieshttps://www.pharmaradar360.com/article/nct07394049-a-prospective-multicenter-cohort-study-of-contemporary-menopausal-ho-ae3c6cd7a8b892b9Pharma Surgeen2026-07-31T00:00:00.000ZNCT07394049: A Prospective Multicenter Cohort Study of Contemporary Menopausal Hormone Therapy and Cardiovascular Outcomeshttps://www.pharmaradar360.com/article/nct07388537-evaluation-of-the-clinical-spectrum-of-diabetes-and-obesity-in-youth-3033397525ec41f9Pharma Surgeen2026-07-31T00:00:00.000ZNCT07388537: Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adultshttps://www.pharmaradar360.com/article/nct07281430-self-collection-for-hpv-testing-to-improve-cervical-cancer-preventio-34feac95ea7adc90Pharma Surgeen2026-07-31T00:00:00.000ZNCT07281430: Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)https://www.pharmaradar360.com/article/nct07281417-testing-the-addition-of-cemiplimab-regn2810-to-chemotherapy-treatmen-a5b3c350c8e1fab2Pharma Surgeen2026-07-31T00:00:00.000ZNCT07281417: Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinomahttps://www.pharmaradar360.com/article/nct07262983-evaluating-the-safety-and-tolerability-of-baricitinib-in-patients-wi-834c49c5b61fdd2aPharma Surgeen2026-07-31T00:00:00.000ZNCT07262983: Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitishttps://www.pharmaradar360.com/article/nct07227532-a-study-assessing-long-term-safety-and-effectiveness-in-treatment-ma-ed047a283f5431e0Pharma Surgeen2026-07-31T00:00:00.000ZNCT07227532: A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter Systemhttps://www.pharmaradar360.com/article/nct07106632-optimising-adjuvant-chemotherapy-prescription-in-young-patients-with-678e3588e1ef5a1dPharma Surgeen2026-07-31T00:00:00.000ZNCT07106632: Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Testshttps://www.pharmaradar360.com/article/nct07062471-study-of-the-shockwave-medical-skyrunner-carotid-intravascular-litho-9b6cac7e82500c76Pharma Surgeen2026-07-31T00:00:00.000ZNCT07062471: Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)https://www.pharmaradar360.com/article/nct07006636-effect-of-watermelon-on-cardiometabolic-health-ee8e61f7bb13e831Pharma Surgeen2026-07-31T00:00:00.000ZNCT07006636: Effect of Watermelon on Cardiometabolic Healthhttps://www.pharmaradar360.com/article/nct06954337-match-up-making-telehealth-delivery-of-cancer-care-at-home-effective-cac10dce0e5894ffPharma Surgeen2026-07-31T00:00:00.000ZNCT06954337: MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trialhttps://www.pharmaradar360.com/article/nct06901531-a-study-of-zolbetuximab-together-with-pembrolizumab-and-chemotherapy-def392f8fcb82573Pharma Surgeen2026-07-31T00:00:00.000ZNCT06901531: A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancerhttps://www.pharmaradar360.com/article/nct06816511-preliminary-explorative-study-of-magnetic-resonance-guided-focused-u-8c8d010d48199f3aPharma Surgeen2026-07-31T00:00:00.000ZNCT06816511: Preliminary Explorative Study of Magnetic Resonance-Guided Focused Ultrasound Surgery in Refractory Obsessive-Compulsive Disorder Patientshttps://www.pharmaradar360.com/article/nct06741969-nipocalimab-in-moderate-to-severe-sjogren-s-disease-b222763cc3ba834aPharma Surgeen2026-07-31T00:00:00.000ZNCT06741969: Nipocalimab in Moderate to Severe Sjogren's Diseasehttps://www.pharmaradar360.com/article/nct06690398-multicenter-study-of-lumateperone-for-the-treatment-of-irritability-d20870f2ed0b62bbPharma Surgeen2026-07-31T00:00:00.000ZNCT06690398: Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patientshttps://www.pharmaradar360.com/article/nct06637332-daptomycin-vs-vancomycin-for-the-treatment-of-methicillin-resistant-ad1bef42464c10b5Pharma Surgeen2026-07-31T00:00:00.000ZNCT06637332: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremiahttps://www.pharmaradar360.com/article/nct06595940-genetic-analysis-of-uncommon-disease-presentations-in-non-us-populat-9a7defcdd77feca2Pharma Surgeen2026-07-31T00:00:00.000ZNCT06595940: Genetic Analysis of Uncommon Disease Presentations in Non-US Populationshttps://www.pharmaradar360.com/article/nct06589804-testing-the-addition-of-anti-cancer-drug-cetuximab-to-standard-of-ca-b67b43e3ad8f5b04Pharma Surgeen2026-07-31T00:00:00.000ZNCT06589804: Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatmenthttps://www.pharmaradar360.com/article/nct06458998-getting-to-implementation-improving-cancer-screening-for-veterans-1d78c6789be3e404Pharma Surgeen2026-07-31T00:00:00.000ZNCT06458998: Getting To Implementation: Improving Cancer Screening for Veteranshttps://www.pharmaradar360.com/article/nct06139016-using-virtual-reality-to-control-the-audio-visual-inputs-during-keta-e06356f0f5f79b29Pharma Surgeen2026-07-31T00:00:00.000ZNCT06139016: Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatmenthttps://www.pharmaradar360.com/article/nct06100744-a-study-to-assess-adverse-events-change-in-disease-activity-and-how-7798262325b53b77Pharma Surgeen2026-07-31T00:00:00.000ZNCT06100744: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumabhttps://www.pharmaradar360.com/article/nct05675410-a-study-to-compare-standard-therapy-to-treat-hodgkin-lymphoma-to-the-197bf22bc09e3437Pharma Surgeen2026-07-31T00:00:00.000ZNCT05675410: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabhttps://www.pharmaradar360.com/article/nct05600894-venetoclax-in-combination-with-astx727-for-the-treatment-of-chronic-06aa53a09e7c435fPharma Surgeen2026-07-31T00:00:00.000ZNCT05600894: Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasmhttps://www.pharmaradar360.com/article/nct05488314-a-study-of-amivantamab-and-capmatinib-combination-therapy-in-unresec-31f161cb0feba342Pharma Surgeen2026-07-31T00:00:00.000ZNCT05488314: A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancerhttps://www.pharmaradar360.com/article/nct05382559-a-study-of-asp3082-in-adults-with-advanced-solid-tumors-fbd4ee84776d9416Pharma Surgeen2026-07-31T00:00:00.000ZNCT05382559: A Study of ASP3082 in Adults With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct05198830-testing-the-addition-of-an-anti-cancer-drug-trc102-to-the-usual-chem-2e7a02e16da5d13cPharma Surgeen2026-07-31T00:00:00.000ZNCT05198830: Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/nct05045820-integrative-medicine-in-pain-management-in-sickle-cell-disease-39ec1d49f17aea1dPharma Surgeen2026-07-31T00:00:00.000ZNCT05045820: Integrative Medicine in Pain Management in Sickle Cell Diseasehttps://www.pharmaradar360.com/article/nct04847453-venetoclax-mln9708-ixazomib-citrate-and-dexamethasone-for-the-treatm-d627915b243c7681Pharma Surgeen2026-07-31T00:00:00.000ZNCT04847453: Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosishttps://www.pharmaradar360.com/article/nct04708431-androgen-receptor-implications-for-health-and-wellbeing-natural-hist-9b55371cd6320739Pharma Surgeen2026-07-31T00:00:00.000ZNCT04708431: Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivityhttps://www.pharmaradar360.com/article/nct04671667-testing-what-happens-when-an-immunotherapy-drug-pembrolizumab-is-giv-cb7ab02ddf76f627Pharma Surgeen2026-07-31T00:00:00.000ZNCT04671667: Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinomahttps://www.pharmaradar360.com/article/nct04616560-trastuzumab-deruxtecan-ds-8201a-for-the-treatment-of-recurrent-or-re-a79a9591f9c0934fPharma Surgeen2026-07-31T00:00:00.000ZNCT04616560: Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumorhttps://www.pharmaradar360.com/article/nct03914300-testing-the-combination-of-cabozantinib-nivolumab-and-ipilimumab-cab-ed9f0b10d6dba7b0Pharma Surgeen2026-07-31T00:00:00.000ZNCT03914300: Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancerhttps://www.pharmaradar360.com/article/nct03842228-testing-the-combination-of-the-anti-cancer-drugs-copanlisib-olaparib-b16c2a6d62f914b1Pharma Surgeen2026-07-31T00:00:00.000ZNCT03842228: Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutationshttps://www.pharmaradar360.com/article/nct03839212-the-happy-older-latinos-are-active-hola-health-promotion-study-in-hi-374f587f9bbe3102Pharma Surgeen2026-07-31T00:00:00.000ZNCT03839212: The Happy Older Latinos Are Active (HOLA) Health Promotion Study in HIV-Infected Latino Menhttps://www.pharmaradar360.com/article/nct03775265-chemoradiotherapy-with-or-without-atezolizumab-in-treating-patients-4253b8ae1d2d3419Pharma Surgeen2026-07-31T00:00:00.000ZNCT03775265: Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/nct03767244-a-study-of-apalutamide-in-participants-with-high-risk-localized-or-l-30e832050af738b6Pharma Surgeen2026-07-31T00:00:00.000ZNCT03767244: A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomyhttps://www.pharmaradar360.com/article/nct03712605-testing-pembrolizumab-versus-observation-in-patients-with-merkel-cel-01b4d4beb552ce85Pharma Surgeen2026-07-31T00:00:00.000ZNCT03712605: Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trialhttps://www.pharmaradar360.com/article/nct03528642-telaglenastat-with-radiation-therapy-and-temozolomide-in-treating-pa-8e65b96fbdbf7f97Pharma Surgeen2026-07-31T00:00:00.000ZNCT03528642: Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytomahttps://www.pharmaradar360.com/article/nct03394365-a-phase-3-study-of-tabelecleucel-for-participants-with-epstein-barr-7990f022cfee48cePharma Surgeen2026-07-31T00:00:00.000ZNCT03394365: A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapyhttps://www.pharmaradar360.com/article/nct02506153-physician-patient-choice-of-either-high-dose-recombinant-interferon-1739626364458018Pharma Surgeen2026-07-31T00:00:00.000ZNCT02506153: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgeryhttps://www.pharmaradar360.com/article/nct02339012-genetic-and-epigenetic-signatures-of-translational-aging-laboratory-5ad886a13569d85ePharma Surgeen2026-07-31T00:00:00.000ZNCT02339012: Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)https://www.pharmaradar360.com/article/nct02314169-nivolumab-with-or-without-ipilimumab-in-treating-patients-with-refra-8b369cac611639b6Pharma Surgeen2026-07-31T00:00:00.000ZNCT02314169: Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancerhttps://www.pharmaradar360.com/article/nct02196181-testing-two-different-treatment-schedules-of-dabrafenib-and-trametin-b3bf0ce40768c110Pharma Surgeen2026-07-31T00:00:00.000ZNCT02196181: Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spreadhttps://www.pharmaradar360.com/article/nct01142388-paclitaxel-with-or-without-cixutumumab-as-second-line-therapy-in-tre-0e7620e8b9e7143aPharma Surgeen2026-07-31T00:00:00.000ZNCT01142388: Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancerhttps://www.pharmaradar360.com/article/nct00977574-paclitaxel-carboplatin-and-bevacizumab-or-paclitaxel-carboplatin-and-b1a2eb04db95a694Pharma Surgeen2026-07-31T00:00:00.000ZNCT00977574: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancerhttps://www.pharmaradar360.com/article/nct00114101-lenalidomide-in-treating-patients-with-multiple-myeloma-undergoing-a-538aca56de771035Pharma Surgeen2026-07-31T00:00:00.000ZNCT00114101: Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplanthttps://www.pharmaradar360.com/article/nct00060541-evaluation-and-treatment-of-neurosurgical-disorders-347be76e6bdc732dPharma Surgeen2026-07-31T00:00:00.000ZNCT00060541: Evaluation and Treatment of Neurosurgical Disordershttps://www.pharmaradar360.com/article/compounding-must-not-become-a-drug-approval-shortcut-for-big-wellness-3f6b4899bf0798f0Pharma Surgeen2026-07-30T22:49:44.000ZCompounding must not become a drug-approval shortcut for Big Wellnesshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-shanghai-fudan-zhangjiang-bio-pharmaceutical-1b18458566ec38c8Pharma Surgeen2026-07-30T22:21:28.000ZEnterprise value to EBIT forward of Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class H – HKEX:1349https://www.pharmaradar360.com/article/cha-biotech-co-ltd-revenue-breakdown-krx-085660-ce2a13d2a5593233Pharma Surgeen2026-07-30T21:55:13.000ZCHA Biotech Co., Ltd. Revenue Breakdown – KRX:085660https://www.pharmaradar360.com/article/outbreak-investigation-of-e-coli-frozen-blueberries-july-2026-ce68aed69780dfb6Pharma Surgeen2026-07-30T21:33:56.000ZOutbreak Investigation of E. coli: Frozen Blueberries (July 2026)https://www.pharmaradar360.com/article/investors-purchase-high-volume-of-put-options-on-teva-pharmaceutical-industries-ffe8cd32f849fd68Pharma Surgeen2026-07-30T21:31:40.000ZInvestors Purchase High Volume of Put Options on Teva Pharmaceutical Industries (NYSE:TEVA)https://www.pharmaradar360.com/article/early-surgery-for-bacterial-eye-infection-offers-hope-to-patients-faad284124f10c5cPharma Surgeen2026-07-30T21:20:06.000ZEarly surgery for bacterial eye infection offers hope to patientshttps://www.pharmaradar360.com/article/pharma-fundamentals-hold-times-in-biopharmaceuticals-an-introduction-af712b2cfb35f27cPharma Surgeen2026-07-30T21:02:36.000ZPharma Fundamentals: Hold Times in Biopharmaceuticals, an Introductionhttps://www.pharmaradar360.com/article/federal-biotech-commission-examines-colorado-s-role-in-critical-minerals-product-73970e3e3cecd01dPharma Surgeen2026-07-30T20:58:57.000ZFederal biotech commission examines Colorado’s role in critical minerals productionhttps://www.pharmaradar360.com/article/leading-oncology-journal-accepts-for-publication-new-cel-sci-multikine-phase-3-d-2a55f5bd23697afaPharma Surgeen2026-07-30T20:39:08.000ZLeading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patientshttps://www.pharmaradar360.com/article/maharashtra-fda-targets-high-drug-prices-seeks-nppa-action-b38f69cc41af6c56Pharma Surgeen2026-07-30T20:37:02.000ZMaharashtra FDA Targets High Drug Prices, Seeks NPPA Action